Asset Details
Do you wish to reserve the book?
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy
Do you wish to request the book?
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy
2014
Overview
Glioblastoma multiforme patients have a poor prognosis due to therapeutic resistance and tumor relapse. It has been suggested that gliomas are driven by a rare subset of tumor cells known as glioma stem cells (GSCs). This hypothesis states that only a few GSCs are able to divide, differentiate, and initiate a new tumor. It has also been shown that this subpopulation is more resistant to conventional therapies than its differentiated counterpart. In order to understand glioma recurrence post therapy, we investigated the behavior of GSCs after primary chemotherapy. We first show that exposure of patient-derived as well as established glioma cell lines to therapeutic doses of temozolomide (TMZ), the most commonly used antiglioma chemotherapy, consistently increases the GSC pool over time both
in vitro
and
in vivo
. Secondly, lineage-tracing analysis of the expanded GSC pool suggests that such amplification is a result of a phenotypic shift in the non-GSC population to a GSC-like state in the presence of TMZ. The newly converted GSC population expresses markers associated with pluripotency and stemness, such as CD133, SOX2, Oct4, and Nestin. Furthermore, we show that intracranial implantation of the newly converted GSCs in nude mice results in a more efficient grafting and invasive phenotype. Taken together, these findings provide the first evidence that glioma cells exposed to chemotherapeutic agents are able to interconvert between non-GSCs and GSCs, thereby replenishing the original tumor population, leading to a more infiltrative phenotype and enhanced chemoresistance. This may represent a potential mechanism for therapeutic relapse.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Animals
/ Antineoplastic Agents, Alkylating - pharmacology
/ Antineoplastic Agents, Alkylating - therapeutic use
/ Basic Helix-Loop-Helix Transcription Factors - metabolism
/ Biomedical and Life Sciences
/ Brain Neoplasms - drug therapy
/ Cell Transformation, Neoplastic - drug effects
/ Dacarbazine - analogs & derivatives
/ Dacarbazine - therapeutic use
/ DNA
/ Humans
/ Male
/ Neoplastic Stem Cells - physiology
/ Surgery
